Outcomes in HIV-infected patients who develop tuberculosis after starting antiretroviral treatment in Malawi

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 6, 2008, Pages 692-694

  Yu, J K L ^a,b,c,d   Bong, C N ^a,b,c   Chen, S C C ^c,e   Dzimadzi, R ^b   Lu, D Y ^f,g   Makombe, S D ^b   Schouten, E J ^b,h   Kamoto, K ^b   Harries, A D ^b,i,j,k  

^a Taiwan Medical Mission in Malawi   (Taiwan)

^b MINISTRY OF HEALTH   (Malawi)

^c PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f Pingtung Hospital   (Taiwan)

^g Bureau of International Cooperation   (Taiwan)

^h Malawi Country Office ^*  (Malawi)

ⁱ FAMILY HEALTH INTERNATIONAL   (United States)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^k Malawi Country Office   (Malawi)

more..

Author keywords

Antiretroviral treatment; HIV AIDS; Malawi; Treatment outcomes; Tuberculosis

Indexed keywords

ETHAMBUTOL; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; RIFATER;

ADD ON THERAPY; ADULT; ARTICLE; CHILD; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED KINGDOM; WEIGHT REDUCTION;

ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; CHILD; COMORBIDITY; HIV INFECTIONS; HUMANS; ISONIAZID; MALAWI; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 45349097916     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Corbett E L, Watt C J, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021.
2. Lawn S D, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long-term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-2116.
3. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment in Abidjan. Am J Respir Crit Care Med 2005; 172: 123-127.
4. Harries A D, Hargreaves N J, Gausi F, Kwanjana J H, Salaniponi F M. High early death rate in tuberculosis patients in Malawi. Int J Tuberc Lung Dis 2001; 5: 1000-1005.
5. Ministry of Health. Treatment of AIDS: guidelines for the use of antiretroviral therapy in Malawi. 2nd ed. Lilongwe, Malawi: Ministry of Health, 2006.
6. Ministry of Health and Population. Manual of the National Tuberculosis Control Programme of Malawi. 5th ed. Lilongwe, Malawi: Ministry of Health and Population, 2002.
7. The Antiretroviral Therapy in Lower-Income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-824.
8. Lawn S D, Myer L, Orrell C, Bekker L-G, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19: 2141-2148.
9. Whalen C C, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiological study in Uganda. AIDS 2000; 14: 1219-1228.
10. Golub J E, Saraceni V, Cavalcante S C, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21: 1441-1448.